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Genetic-dissection studies carried out with Down syndrome (DS) murinemodels point to the critical contribution of Dyrk1A overexpres-
sion to the motor abnormalities and cognitive deﬁcits displayed in DS individuals. In the present study we have used a murine model
overexpressing Dyrk1A (TgDyrk1Amice) to evaluate whether functional CNS defects could be corrected with an inhibitory RNA against
Dyrk1A, delivered by bilateral intrastriatal injections of adeno-associated virus type 2 (AAVshDyrk1A). We report that AAVshDyrk1A
efﬁciently transduced HEK293 cells and primary neuronal cultures, triggering the speciﬁc inhibition of Dyrk1A expression. Injecting
the vector into the striata of TgDyrk1Amice resulted in a restricted, long-term transduction of the striatum. This gene therapy was found
to be devoid of toxicity and succeeded in normalizing Dyrk1A protein levels in TgDyrk1A mice. Importantly, the behavioral studies of
the adult TgDyrk1A mice treated showed a reversal of corticostriatal-dependent phenotypes, as revealed by the attenuation of their hy-
peractive behavior, the restoration of motor-coordination defects, and an improvement in sensorimotor gating. Taken together, the data
demonstrate that normalizing Dyrk1A gene expression in the striatum of adult TgDyrk1Amice, by means of AAVshRNA, clearly reverses
motor impairment. Furthermore, these results identify Dyrk1A as a potential target for therapy in DS.Introduction
Down syndrome (DS [MIM 190685]) is a multisystem
disorder resulting from the presence of an extra copy of
the human chromosome 21 (HSA21, Homo sapiens auto-
some 21). Although HSA21 contains more than three hun-
dred genes, those contributing to DS phenotypes are likely
to be considerably less.1 In fact there is a current debate
regarding whether few genes with a strong impact might
be participating in a given phenotype or whether such
a phenotype will result from the impact of multiple genes
with modest effects. Interestingly, the genes implicated in
the trisomy are nonmutated genes, and thus it is only 50%
overexpression that contributes to the overall effects.2
DYRK1A [MIM 600855], one of the triplicated genes in
trisomy 21, has been demonstrated to be 1.5-fold overex-
pressed in DS brains, both at transcript and protein levels,
indicating that this protein is overexpressed in a gene-dos-
age-dependent manner.3,4 DYRK1A encodes for dual-spec-
iﬁcity tyrosine-(Y)- phosphorylation regulated kinase 1A,
an enzyme deﬁned as dual-substrate speciﬁc because it
autophosphorylates on Tyr-321 and in Ser/Thr and phos-
phorylates target proteins on serine/threonine residues.5
A variety of substrates and interacting proteins have been
described,6 suggesting that DYRK1A may be participating
in multiple biological pathways. Functional evidences
revealing the contribution of DYRK1A overexpression in
a DS phenotype comes mainly from studies on different
genetically engineered mice. In this respect, transgenic
mice overexpressing Dyrk1A display cognitive deﬁcitsand motor abnormalities,7–10 as well as vascular defects.11
All these evidences suggest that strategies directed toward
reducing Dyrk1A overexpression might be considered as
a potential approach to correct speciﬁc DS phenotypic
alterations dependent on Dyrk1A overexpression. The spe-
ciﬁc inhibition of Dyrk1A could be achieved by the use of
small interfering RNA (siRNA) approaches, employing an
efﬁcient delivery system that targets neuronal cells.
Adeno-associated viruses have been shown to effectively
deliver genes and shRNA sequences to the CNS, thereby
mediating long-term transgene expression with limited
immune response.12
In the present study, we explore the possibility that by
subtly reducing Dyrk1A in the brain of adult TgDyrk1A
mice by adeno-associated virus delivery of an shRNA
sequence speciﬁc for Dyrk1A, it may be feasible to correct
the motor abnormalities present in these mice.
Material and Methods
Plasmid Constructs
pU6-shDyrk1A and p-U6scDyrk1A were generated as follows: A
sh1073Dyrk1A sequence was designed to target 1073–1083 bp
within the rat Dyrk1A open reading frame. The sc1073Dyrk1A se-
quence consisted of a scrambled version of the sh1073Dyrk1A
sequence. We generated the sh1073Dyrk1A and sc1073Dyrk1A
by synthesizing two pairs of 54-mer oligonucleotides containing
(1) a 20-nucleotide sense strand and a 20-nucleotide antisense
strand, separated by a six-nucleotide loop (HindIII restriction site:
AAGCTT); (2) a stretch of ﬁve timidines as a termination signal;
and (3) 2G at the 50 and30 ends. Sequence sh1073Dyrk1A (in italics,1Programa Gens i Malaltia. Centre de Regulacio´ Geno`mica-CRG, UPF, Parc de Recerca Biome`dica de Barcelona-PRBB, Barcelona 08003, Spain; 2Centro de
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sense and antisense strands; underlined, loop) is as follows: sense
oligonucleotide: 50-GGGCAGAGGATATACCAGTATAAGCTTATAC
TGGTATATCCTCTGCCCTTTTTG-30. Sequence sc1073Dyrk1A is
as follows: sense oligonucleotide 50-GGGCCCTCCATCACAGTCTA
TAACCTTATAGACTGTGATGGAGGGCCCTTTTTG-30. Sense and
antisense oligonucleotides of each pair were annealed and cloned
in the ApaI and EcoRI sites of a modiﬁed pBluescript plasmid that
contained the U6 promoter.13
Cell Culture and Transfection
HEK293 and COS-7 cells were plated at a density of 2 3 105 or 13
106 cells/well, respectively, in 60mm dishes with Dulbecco’s mod-
iﬁed Eagle’s medium (DMEM), supplemented with 5% fetal-calf se-
rum (FCS) and antibiotics. Transfection of the different plasmids
used in the study (pU6shDyrk1A, GFP-Dyrk1A, GFP-NHDyrk1A,
and HA-RCAN1) was performed with Superfect Transfection Re-
agent (QIAGEN), in accordance with the manufacturer’s instruc-
tions. Cells were harvested and processed 48 hr after transfection.
Primary Cell Culture
A primary culture ofmouse cerebellar granule neurons (CGNs) was
prepared as previously reported,14 with certain modiﬁcations. In
brief, the cerebella of 7-day-old mouse pups were dissected in
ice-cold Kreb’s solution, diced, and dissociated with trypsin at
37C. The dissociated cells were seeded at 3 3 105 cells/cm2 onto
a poly-L-lysine (Sigma)-coated culture dish (12-mm diameter; Bec-
ton Dickinson). Cells were cultured in DMEM supplemented with
10% FCS containing 25 mM KCl and were incubated at 37C in
humidiﬁed 5% CO2. After 1 day in vitro (DIV 1), one volume of
Neurobasal medium (Invitrogen), containing 25 mM KCl supple-
mented with 20 mM cytosine arabinoside (Ara-C) (Sigma), was
added to the cultures. For preparation of the total cell extracts,
CGNs were rinsed twice with PBS, collected in 100 ml of SDS-sam-
ple buffer, boiled for 10 min at 98C, and analyzed with SDS-PAGE
and immunoblotting.
Immunoﬂuorescence
Cells were seeded at a density of 2 3 105 cells/well on sterile
coverslips in 12-well plates and ﬁxed in 4% paraformaldehyde.
Cells were rinsed in PBS and permeabilized with PBS-0.1% Triton
X-100 for 15 min at room temperature. Blocking was performed
with PBS-10% FBS for 1 hr at room temperature. Then cells were
incubated with rabbit anti-GFP (1:2500; Invitrogen) for 1 hr at
room temperature, rinsed three times with PBS-0.1% Triton
X-100-1% FBS and incubated with mouse anti-rabbit secondary
antibody conjugated to FITC (1:100; Southern Biotechnologies)
for 1 hr. Cells were then washed and mounted in a medium
containing 0.2 mg/ml 4,6-diamidino-2-phenilindole (DAPI) for
nuclear visualization (Vectashield, Vector). Preparations were visu-
alized on a Leica DMRmicroscope. Images were taken with a Leica
DC500 camera and processed on Leica IM1000 software.
Immunoblotting
Adult mouse striata homogenates and cell-culture extracts were
obtained as follows: In brief, the striata weremechanically homog-
enized in a glass potter with a lysis buffer containing 320 mM
sucrose, 50 mM Tris-HCl (pH 7.4), 10 mM EDTA, 1 mM PMSF,
and protease inhibitor cocktail (Complete Mini, Roche). The ho-
mogenates were centrifuged for 10 min at 800 g at 4C, and the
supernatant was collected for further analysis. Primary granular
neurons, HEK293 and COS-7 cells, were homogenized in 100 ml480 The American Journal of Human Genetics 83, 479–488, Octobelysis buffer (SDS 1% in PBS). Protein concentration was deter-
mined by a BCA assay (Pierce Biotechnology). Equal amounts of
protein (80 and 30 mg for striata and cellular extracts, respectively)
were loaded and separated on a 7.5% SDS-PAGE and were trans-
ferred onto nitrocellulose membranes (Amersham). Membranes
were blocked with 5% nonfat milk in PBS-0.1% Tween-20
(PBS-T) solution and incubated overnight, with a polyclonal anti-
body against Dyrk1A (1:250)15 contained in the same incubation
solution. The protein loading was monitored with a polyclonal
antibody against b-Actin (1:2000; Sigma). Incubation with anti-
rabbit or anti-mouse IgG/HRP (horseradish peroxidase) antibodies
(1:2000; Dako) was performed for 1 hr at room temperature.
Immunocomplexes were detected by chemiluminescence on an
ECL detection system (Pierce), according to the manufacturer’s
instructions.
Recombinant Production of Adeno-Associated
Viral Vector
The adeno-associated viral serotype 2 (AAV2) vectors used in the
study were as follows: AAVshDyrk1A (expression cassette includes
a hairpin-forming sequence against Dyrk1A gene under the con-
trol of the U6 promoter and the ﬁreﬂy luciferase gene under the
control of the CMV promoter) and AAVscDyrk1A (expression cas-
sette includes a hairpin-forming scrambled version obtained from
the shDyrk1A sequence under the control of the U6 promoter and
the ﬁreﬂy luciferase gene under the control of the CMVpromoter).
Both AAV2 vectors were produced in the Centre for Animal
Biotechnology and Gene Therapy of the Universitat Autonoma
of Barcelona (CBATEG-UAB) as previously described.16 The re-
combinant viruses were puriﬁed by iodixanol ultracentrifugation
gradient and concentrated by application to an Amicon Ultra
100 kDamembrane. Theywere then resuspended in a PBS solution
containing 1mM MgCl2 and 2.5 mM KCl. The titers were
AAVshDyrk1A (5.213 1011 genome copies/ml) and AAVscDyrk1A
(5.25 3 1011 genome copies/ml).
AAV Infection of HEK293 Cells and CGNs
One day before infection, HEK293 cells or CGNs were seeded at
a density of 1 3 103 or 1.25 3 105 cells/well, respectively, in
96-well plates. The virus was added to themedium at the indicated
doses and removed 24 hr or 6 hr after infection (for the HEK293
cells and CGNs, respectively).
Quantiﬁcation of Luciferase Expression
Luciferase transgene expression was measured in cell lysates or in
the different brain areas in accordance with the manufacturer’s in-
structions (Luciferase Assay System; Promega) and was normalized
to total protein levels. An Orion microplate luminometer (Bert-
hold Detection Systems) or a tube luminometer Autolumat Plus
LB953 (Berthold) were respectively used to analyze the in vitro
or in vivo samples. Protein concentration was determined with
a BCA protein assay (Pierce Biotechnology). Results are expressed
in RLU (relative light units, light units per mg protein).
Immunohistochemistry
Adultmice (3 to 10months old)were deeply anaesthetized andper-
fused transcardially with cold PBS and subsequently with buffered
4% paraformaldehyde in PBS. After ﬁxation, brains were removed
from the skull and immersed in the same ﬁxative overnight.
For luciferase and DARPP-32 detection, after rinsing in PBS, the
brains were dehydrated and embedded in parafﬁn, and 5-mm-thickr 10, 2008
sections were obtained with a sliding microtome (Leica). Sections
were processed by the avidin-biotin-peroxidase method (Kit ABC,
Dako), with a prior treatment in citrate buffer (pH 6.0) for antigen
retrieval. After washing twice with water and PBS, the endogenous
peroxidases were inactivated and tissue sections were incubated
with blocking solution (PBS supplemented with 0.2% Triton X-
100, 10% FBS, and 0.25% gelatine) for 1 hr at room temperature.
Sections were then incubated overnight at 4C with the primary
monoclonal anti-DARPP-32 antibody (1:100; Cell Signaling),
with the polyclonal anti-Luciferase antibody (1:1000; Sigma), or
in the absence of primary antibody (for the negative control) in
PBS with 0.2% Triton X-100 and 1% FBS. Subsequently, the sec-
tions were incubated with ABC solutions in accordance with the
manufacturer’s instructions. Peroxidase activity was visualized
with 0.05% diaminobenzidine and 0.01% hydrogen peroxide.
No immunoreaction was detected in the sections omitting the
primary antibody, thus conﬁrming the speciﬁcity of the reaction.
All the sections were visualized on anOlympusmicroscope (Olym-
pus BX51). Images were taken with an Olympus DP70 camera.
Animals
Transgenic mice (TgDyrk1A) overexpressing the full-length rat
Dyrk1A cDNA under the control of the sheep metallothionein-Ia
promoter have been previously described by our group.10
TgDyrk1A mice were maintained as hemizygotes on a C57BL/
6JXSJL background and housed under a 12:12 hr light-dark sched-
ule (lights on at 8:00 a.m.) in controlled environmental conditions
of humidity (60%) and temperature (22C 5 2C) with food and
water ad libitum. The nontransgenic littermates of the TgDyrk1A
mice served as controls. Only males were tested in this study.
The number of animals used for each test was as follows:
14 mice/group (actimetry test), six mice/group (treadmill test),
and sevenmice/group (prepulse inhibition test). All the behavioral
testing was conducted by the same experimenters, in an isolated
room and at the same time of day. The behavioral experimenters
were blinded as to the genetic and treatment status of the animals.
All animal proceduresmet the guidelines of EuropeanCommunity
Directive 86/609/EEC and were approved by the Local Ethics
Committee.
Stereotaxic Injection
Adult (2- to 3-month-old) male TgDyrk1A and control mice were
anesthetized with a combination of medetomidine (Domtor,
Pﬁzer) and ketamine (Imalgene 500, Merial) at a dose of 1 mg/kg
and 75 mg/kg, respectively. Then they were securely placed in a
stereotaxic frame (Harvard Apparatus). The injections were
performed bilaterally into the striatum at selected coordinates
(AP þ0.7 mm, L 5 2.0 mm, DV 3.0 mm relative to bregma)
with a 5 ml Hamilton syringe. Three ml were injected per hemi-
sphere at a rate of 0.2 ml/min in a two-step manner. Half the vol-
ume, 1.5 ml, was ﬁrst injected at 3.00 mm DV, then the other
half was injected at 2.5 mm DV. The rate of injection was pre-
cisely controlled by an infusion pump (Ultramicropump, World
Precision Instruments). The needle was left in place for 5 min after
the last injection and then slowly retracted from the brain. Before
totally withdrawing, the needle was left in place for an additional
5 min. After the surgical intervention, animals were injected sub-
cutaneously with a dose of 2 mg/kg of atipamezole (Antisedan,
Pﬁzer) for anesthetic reversal. The analgesic buprenorphine
(Buprex, Schering-Plough) was also administered intraperitoneally
at a dose of 0.05 mg/kg every 8 hr for 48 hr after intervention.The AmericWhen stated brains were sliced in 1-mm-width coronal sections
with a Tissue Chopper (McIllwain, PANLAB S.L.)
In Vivo Bioluminescence
The luciferase activity was visualized with an in vivo biolumines-
cence imaging system (IVIS; Xenogen/Caliper Life Sciences). The
images were captured and analyzed on Living Image 2.20.1 soft-
ware (Xenogen/Caliper Life Sciences) and overlaid on Igor Pro
4.06A software (WaveMetrics). In brief, the animals were anesthe-
tized and the substrate ﬁreﬂy D-luciferin (Xenogen/Caliper Life
Sciences) was administered intraperitoneally (16 mg/kg). The bio-
luminescent images were acquired 14 min after administration of
the substrate and after carrying out an initial optimization study.
For the purpose of visualization, a light image of the animal was
also taken and merged with the bioluminescent image with the
software’s overlaymode. This enabled the area of luciferase expres-
sion to be precisely correlated with the corresponding area of the
mouse brain anatomy. The results are expressed as photons per
second per square centimeter and per steradian.
Behavioral Analysis
Locomotor Activity
We measured locomotor activity by using actimetry boxes (45 3
45 cm; Harvard Apparatus) contained in a soundproof cupboard.
Back and forward movements were monitored via a grid of infra-
red beams and used as an index of locomotor activity (counts).
Counts were integrated every hour and added to obtain total loco-
motor activity for a 24 hr period maintaining the 12:12 hr light-
dark schedule. The parameter measured in the present study was
the total distance traveled by the animals (cm).
Treadmill Performance
Thetreadmill (HarvardApparatus) consistedofabelt (50cmlongand
20cmwide) thatwas runat avarying speed (5 to150cm1) andslope
(0–45). At the endof the treadmill, therewas anelectriﬁed grid that
gave themice a shock on the foot (0.4mA)whenever they fell off the
belt. Standard conditions were applied before intervention, consist-
ing of the setting of consecutive trials of increasing difﬁculty (speed:
10, 20, 30, 40 cm1; slope: 20). Forced conditions were applied after
intervention, consistingof applyingone single trial (speed: 60 cm1;
slope:40). The cutoff timewas at1minper trial.Theorderof presen-
tation of the different belt speeds and slopes was identical for all
mice. The mice were placed on the top of the already-moving belt,
facing away from the electriﬁed grid and in the opposite direction
to the travel of the belt. Thus to avoid electric shocks the mice had
to move forward. Whenever an animal fell from the belt, electrical
shocks were applied to its paws for a maxim of 1 s. The results were
processed with a one-way ANOVA statistical test.
Prepulse Inhibition of Startle Reflex
The apparatus used consisted of a chamber (Harvard Apparatus)
containing anonrestrictive cylindrical enclosuremadeof clear Plex-
iglas attachedhorizontally to a lightweightmobile platform that, in
turn, restedon a solid base inside a sound-attenuated isolation cubi-
cle. Acoustic noise bursts were presented via a speaker mounted
24 cm above the tube. Throughout the session, a background noise
level of 70 db was maintained. A piezoelectric accelerometer
mounted below the frame detected and transduced motion within
the tube. Startle amplitudes were deﬁned as the average of the sta-
bilimeter readings collected from the onset of the stimulus. The
micewere tested individually. Eachmousewasput into theprepulse
inhibition(PPI) chamberand, followinga5minhabituationperiod,
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were used: no-stimulus trials, trials with an acoustic startle stimulus
alone (120 dB), and trials in which a prepulse stimulus (74, 78, 82,
86, or 90 dB) was provided 100 ms prior to the startle stimulus.
The different trials were presented in a randomorder, with an inter-
trial interval of 15 s. The startle amplitude, deﬁned as the peak
response beginning at the onset of the startle stimulus, was mea-
sured for each trial. The levels of PPI at each prepulse sound level
were calculated as 100  [(response amplitude for prepulse-pulse
stimulus/response amplitude for startle stimulus alone)3 100].
Statistical Analysis
The statistical analysis on the behavioral studies was performed
with one-way ANOVA whenever the factors were found to display
signiﬁcant interaction. Data are reported asmean5 standard error
of the mean (SEM). The statistical analysis was performed on SPSS
12.0 software. Student’s t test was applied for evaluation of
statistical signiﬁcance in the luciferase assay. The cutoff point for
signiﬁcance was considered as p < 0.05.
Results
AAVshDyrk1A Reduces Dyrk1A Expression In Vitro
The targeting of Dyrk1Awas designed in silico by the selec-
tion of three different 20-nucleotide target sequences of
Figure 1. Generation and In Vitro Char-
acterization of AAV-shRNA Targeting
Dyrk1A
(A) Diagram of the recombinant AAV2/2
viral vectors containing the hairpin se-
quences under the control of the mouse
U6 promoter and the firefly luciferase re-
porter gene under the control of the CMV
promoter AAVshDyrk1A and AAVscDyrk1A.
(B and C) Determination of luciferase
activity in HEK293 cells (B) and primary
cultures of CGNs (C) infected at 50, 100,
and 500 MOI with the AAVshDyrk1A or
AAVscDyrk1A virus. Data are expressed in
relative light units (RLU or LU/mg). Values
are expressed as mean 5 SEM of three
independent experiments.
(D and E) Western blot showing Dyrk1A
levels in control mock infected cultures
(C) or after infection with 50, 100, and
500 MOI of AAVshDyrk1A and AAVscDyrk1A
in HEK293 cells (D) or 500 MOI of AAVsh-
Dyrk1A in CGNs (E). Actin was used as an
internal control. Bars show densitometric
analysis of the Dyrk1A band normalized
against the actin band.
the open reading frame, conserved
in human, mouse, and rat Dyrk1A,
encompassing nucleotides ranging
from 1073 to 1092, 2002 to 2021,
and 1132 to 1151 from the rat cDNA
sequence. We constructed expression
cassettes driving short hairpin RNA
(shRNA) by the U6 promoter and
screened in vitro them in order to identify the most efﬁ-
cient and speciﬁc shRNAs against Dyrk1A. Initially, the
screening was performed in COS-7 cells cotransfected
with the inhibitory plasmids and a plasmid encoding for
GFP-Dyrk1A (Dyrk1A in-frame with the GFP). Western-
blot and immunoﬂuorescence analysis revealed the inhib-
itory effect of the sh1073Dyrk1A sequence; such an effect
promoted a decrease in GFP-Dyrk1A protein expression.
Conversely, neither the expression of the unrelated gene
RCAN1 or the truncated form of Dyrk1A (GFP-NHDyrk1A),
lacking the target sequence for the sh1073RNA, were af-
fected, indicating the speciﬁcity of sh1073Dyrk1A to the
targeted sequence of Dyrk1A (Figure S1 available online).
The selected U6-sh1073RNA and its related scrambled
control (sc) expression cassettes were cloned into AAV2
vectors (Figure 1A). We also modiﬁed the viral genome of
the AAVs with the insertion of the ﬁreﬂy luciferase gene
under the control of a CMV promoter to monitor cellular
transduction. Infection of HEK293 cells and primary
cultures of cerebellar granular neurons (CGN) showed
a similar dose-response effect in the luciferase activity of
both viruses (AAVsh Dyrk1A and AAVscDyrk1A). The
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Figure 2. Follow-Up of Luciferase Expression after Intrastriatal Injection of AAVshDyrk1A of TgDyrk1A Mice
(A) In vivo bioluminescence detection of luciferase activity in live animals and ex vivo sliced brains (slice width of 1 mm). Units are
expressed as total photon counts. A viral dose of 1 3 109 vp in a 3 ml total volume was injected per hemisphere. Red dot indicates
stereotaxic injection coordinates. Animals were sacrificed 2 weeks after injection.
(B) Quantification of the luciferase activity present in the extracts of different brain areas 20 days after intrastriatal injection of AAVsh-
Dyrk1A (STR, striatum; CO, cortex; CB, cerebellum). Data are expressed in RLU. Values are expressed as mean 5 SEM (n ¼ 4 mice).
(C) Time course of luciferase expression after intrastriatal administration of AAVshDyrk1A. Animals were sacrificed at different days
after intervention. Data are given in RLU. Values are expressed as mean5 SEM (n ¼ 4 mice). The asterisk indicates significance with a
p value < 0.05.transduction efﬁciency was higher in the HEK293 cells
than in the CGNs, as detected by luciferase-activity mea-
surement (Figures 1B and 1C). The inhibitory efﬁciency
of the AAVshDyrk1Awas assessed by western-blot analysis,
showing that AAVshDyrk1A, but not control AAVsc-
Dyrk1A, reduced endogenous Dyrk1A protein expression
in HEK293 cells in a dose-response manner (Figure 1D).
An inhibitory effect of the AAVshDyrk1A was also ob-
served in mouse CGNs, although a higher viral dose of
500 MOIs was required (Figure 1E).
AAVshDyrk1A Gene Transfer to the Striatum Reduces
Dyrk1A Gene Expression
We next investigated whether the viral particles generated
were capable of efﬁciently infecting the striatum of
TgDyrk1A mice. Taking advantage of the fact that both
viruses contained a luciferase reporter, we monitored theThe Americlevels, biodistribution, and kinetics of the viral infections
with in vivo bioluminescence and by biochemically deter-
mining luciferase activity in brain extracts. Biolumines-
centmeasurement of the light emitted in livemice, 2 weeks
after viral injection, showed efﬁcient transduction of the
viral particles. Luciferase expression extended up to
2 mm along the rostrocaudal axes, as shown by the analy-
sis of 1-mm-thick coronal brain sections (Figure 2A). In-
deed, luciferase activity was mostly restricted to the brain
area corresponding to the striatum (Figure 2B). Kinetic
studies showed that luciferase expression peaked between
10 to 20 days after injection and signiﬁcantly decreased
4 months later (Figure 2C). This reduction in luciferase ex-
pression could probably be related to the described epige-
netic inactivation of the CMV promoter and independent
of viral transduction.17 In fact, western-blot analysis of
Dyrk1A indicated that Dyrk1A levels in the striatum ofan Journal of Human Genetics 83, 479–488, October 10, 2008 483
Figure 3. Kinetics of Dyrk1A Inhibition in the Striatum of TgDyrk1A Mice after AAVshDyrk1A Administration
Western-blot analysis of Dyrk1A protein levels. (A) shows representative images of Dyrk1A expression from striata ipsilaterally injected
with AAVshDyrk1A and contralaterally injected with AAVscDyrk1A at 1, 2, 3, and 4 months after injection. Bars show densitometric anal-
ysis of the Dyrk1A band, normalized against the actin band and represented as the ratio of shDyrk1A versus scDyrk1A signal. Data are
expressed as the mean5 SEM (n¼ 4 mice). (B) shows a representative western blot of Dyrk1A expression from TgDyrk1A striata injected
with AAVshDyrk1A or with AAVscDyrk1A and from wild-type mice injected with saline. Bars show densitometric analysis of Dyrk1A signal
from striata normalized to Dyrk1A hippocampal levels. Data are expressed as the mean5 SEM (n¼ 4 mice). Actin was used as an internal
control.TgDyrk1A mice injected with AAVshDyrk1A were efﬁ-
ciently reduced in vivo at all the time points analyzed (Fig-
ure 3A). Interestingly, this inhibitory effect was still pres-
ent 8 months after AAVshDyrk1A injections in TgDyrk1A
mice striata, with a reduction of Dyrk1A to levels that
were similar to those of wild-type animals (Figures 3B
and 3C).
Although the use of adeno-associated vectors is virtually
devoid of toxicity to the central nervous system, putative
neurotoxicity associated to shRNA sequences has recently
been reported.18 To examine any striatal damage, we
performed an immunohistochemical analysis of the dopa-
mine and cAMP-regulated phosphoprotein (DARPP-32),
a marker of medium-sized spiny-projection neurons in
the striatum, reported as an indicator of shRNA toxicity
in the striatum,18 in coronal sections of AAVshDryrk1A-
treated mice, harvested at 2 weeks and 8 months after in-
tervention. No differences in DARPP-32 immunoreactivity
were observed when we compared the DARPP-32 signal of
the hemisphere injected with AAVshDyrk1A to that of the
contralateral, which received saline solution alone (Fig-
ure 4). Luciferase-positive cells were immunostained in
the AAVshDyrk1A hemisphere, indicating viral trans-
duction (Figure 4). No changes in DARPP-32 immuno-
reactivity were observed in the striatum of the saline-,484 The American Journal of Human Genetics 83, 479–488, OctobeAAVscDyrk1A-, and AAVshDyrk1A-treated mice 8 months
after intervention (data not shown).
Striatal Delivery of AAVshDyrk1A Attenuates Motor
Alterations in Adult TgDyrk1A Mice
To investigate the effects of inhibiting Dyrk1A overexpres-
sion in the case of established TgDyrk1A motor deﬁcits, we
injected AAVshDyrk1A into the striatum of 2- to 3-month-
old adult TgDyrk1A mice and performed behavioral phe-
notyping at preinjection and different postinjection time
points. TgDyrk1A mice were randomly assigned to three
groups bilaterally receiving AAVshDyrk1A, AAVscDyrk1A,
or saline, along with a group of wild-type mice injected
with saline. Circadian activity under basal conditions was
assessed by the actimetry box test. In preinjection sessions,
although no differences were observed in the circadian
rhythms, TgDyrk1A mice showed a greater total distance
traveled in 24 hr compared to that of wild-type mice, indi-
cating a hyperactive phenotype (Figure 5A; p < 0.05; n ¼
14). Two months after intervention, a reduction in hyper-
active behavior was observed only in the TgDyrk1A mice
injected with AAVshDyrk1A. Their total activity was lower
than that of the TgDyrk1A mice injected with saline alone
(Figure 5A; p < 0.05; n ¼ 14) or with AAVscDyrk1A (Fig-
ure 5A; p ¼ 0.09). Importantly, 4 months after injection,r 10, 2008
a far more signiﬁcant reduction in activity was observed in
the TgDyrk1A mice treated with AAVshDyrk1A than in
those treated either with AAVscDyrk1A (p < 0.01) or saline
(p < 0.05) (Figure 5A; n ¼ 14), thereby achieving levels of
activity similar to those detected in wild-type mice thus
indicating a complete reversal of hyperactivity by Dyrk1A
expression normalization.
Next, we investigated the effects of AAVshDyrk1A treat-
ment on motor coordination of TgDyrk1A mice that was
previously demonstrated to be signiﬁcantly affected by
using a treadmill test.8 TgDyrk1A mice performed the task
signiﬁcantly worse than wild-type mice, as revealed by the
higher number of shocks received (Figure 5B; p < 0.005;
n ¼ 6). When mice were submitted to the task at 1 month
after treatment, at 40 slope and a speed of 60 cm1,
TgDyrk1A mice injected with AAVshDyrk1A showed a sig-
niﬁcant improvement in the performance of the task, as
reﬂected by the fact that they received less shocks than the
TgDyrk1A mice injected either with AAVscDyrk1A (p <
0.05) or saline (p < 0.05). The AAVshDyrk1A-treated mice
Figure 4. Analysis of AAVshDyrk1A Striatal Toxicity
Animals were stereotaxically injected with saline in the striata
ipsilateral hemisphere and with AAVshDyrk1A in the contralateral
hemisphere. Immunohistochemical staining of DARPP-32 and
luciferase was performed on coronal sections of brains harvested
2 weeks after injection, with an anti-DARPP32 monoclonal and
anti-luciferase polyclonal antibody, respectively. Representative
photomicrographs of DARPP-32-positive medium spiny neurons
(upper panel) and luciferase-positive neurons (lower panel) are
shown. The scale bar represents 1 mm for the upper panel and
200 mm for the lower panel (100 mm for higher magnification).The Americperformed the task at a similar level to that of the saline-
injected wild-type mice (Figure 5B; n ¼ 6). In these groups
ofmice, higher-demanding conditions had to be applied be-
cause of the habituation and learning effect detected when
we used the same experimental conditions. Notably, this
amelioration in motor-coordination skills was likewise
observed 4 months after intervention, when the animals
were sacriﬁced (Figure 5B; p < 0.05; n ¼ 6).
The striatum forms part of the cortico-striato-pallidal
circuitry, also involved in sensorimotor gating.19 To assess
any possible deﬁcits in this function, we measured the
levels of the PPI mechanism, an operational measure of
sensorimotor gating.20 TgDyrk1A mice showed a decrease
in PPI levels that was more pronounced at the higher pre-
pulse intensities used. These results suggested the presence
of deﬁcits in sensorimotor gating, although the differences
did not reach statistical signiﬁcance (Figure 5C; n ¼ 7).
Whenwe repeated the test 4months after injection, we ob-
served an important increase in the PPI levels of the group
of TgDyrk1A mice that had received AAVshDyrk1A, as
compared to those of the AAVscDyrk1A-treated group.
The increase was signiﬁcant at the prepulse intensities of
74 dB and 86 dB (Figure 5D; p < 0.05; n ¼ 7). Furthermore,
the TgDyrk1A mice that received AAVshDyrk1A were the
only treated group that showed a signiﬁcant improvement
in PPI at the different time point analyzed, achieving statis-
tical signiﬁcance 2 and 4 months after the intervention at
a prepulse intensity of 78 dB (Figure 5E; p < 0.05; n ¼ 7).
Discussion
Viral delivery of shRNA candidates presents an alternative
approach to mouse genetic engineering with which to
understand pathophysiology and test potential therapeu-
tic targets. In the present study, we demonstrate that
AAVshRNA strategies are an effective way to study the im-
pact of single-gene downregulation in adult mice, within
the context of phenotypes deriving from nonmutated
gene overexpression. We demonstrate that intrastriatal
injections of AAVshDyrk1A in TgDyrk1A mice normalize
Dyrk1A gene expression in the striatum and correct
established motor alterations.
The efﬁcacy of such approach in normalizing Dyrk1A
content in TgDyrk1A mice probably resulted from both,
the use of the AAV2 serotype virus that stably transduces
neuronal cells in the striatum at a moderate efﬁciency
and the selected applied dose of 109 viral genomes per
hemisphere.
It is worth noting that, to our knowledge, this is the ﬁrst
study that demonstrates effective in vivo correction of an
RNAi approach in a mouse model that displays Down
syndrome-related phenotypes.
To date, few studies have shown a potential to rescue DS
phenotypes, and all have been based on pharmacological
intervention in mouse models. It has recently been shown
that chronic treatment with GABA antagonists in Ts65Dnan Journal of Human Genetics 83, 479–488, October 10, 2008 485
Figure 5. Behavioral Analysis of Motor Tasks in TgDyrk1A Treated with Intrastriatal Injections of AAVshDyrk1A
Animals were randomly assigned to four treatment groups: wild-type (saline) and TgDyrk1A (saline, AAVshDyrk1A, and AAVscDyrk1A).
(A) Actimetry test. The results are given as total distance traveled by the animals in 24 hr expressed in cm. Preinjection results confirmed
the hyperactive phenotype of TgDyrk1A mice compared to the control group (F1,52 ¼ 4.898, *p ¼ 0.031). Two months after the inter-
vention, a decrease in the hyperactivity was observed in TgDyrk1A mice injected with AAVshDyrk1A (TG sh) with respect to saline (TG
sal), (F1,23 ¼ 4.286, *p ¼ 0.05). This reduction became more evident when repeating the test 4 months after treatment (TG sal versus
TG sh: F1,24 ¼ 5.225, *p ¼ 0.032; TG sc versus TG sh: F1,23 ¼ 9.05, **p ¼ 0.006), (n ¼ 14 mice/group).
(B) Treadmill test. The results are expressed as the total number of shocks received. Nontreated mice confirmed the presence of motor-
coordination alterations in TgDyrk1A mice (F1,22 ¼ 11.937, **p ¼ 0.002). One month after the intervention, the AAVshDyrk1A TgDyrk1A
group received a significantly less number of shocks compared to the groups of TgDyrk1A injected with either saline or AAVscDyrk1A,
reaching levels similar to those of control groups (TG sal versus TG sh: F1,6 ¼ 8.669, *p ¼ 0.032; TG sc versus TG sh: F1,8 ¼ 9.844,
*p ¼ 0.016). This effect was maintained 4 months after treatment in AAV-shDyrk1A TgDyrk1A mice (TG sal versus TG sh: F1,10 ¼
5.575, *p ¼ 0.043; TG sc versus TG sh: F1,10 ¼ 6.094, *p ¼ 0.033), (n ¼ 6 mice/group).
(C–E) Prepulse inhibition (PPI) test. Results are expressed as the percentage of inhibition, that refers to the decrease in the amplitude of
the startle response to a given acoustic pulse (120 dB) when it is preceded by a prepulse (74, 78, 82, 86, and 90 dB). As shown in (C),
results before the intervention indicated deficits in the PPI in TgDyrk1A mice, as shown by a tendency to decreased PPI at higher prepulse
intensities. As shown in (D), 4 months after the injection, AAVshDyrk1A TgDyrk1A showed a statistically significant increase in PPI at
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mice, a trisomy model of DS, leads to a recovery of cogni-
tion and long-term potentiation phenotypes, indicating
that the intellectual disabilities associated with DS could
potentially be corrected.21 Improvement in the behavioral
performance of Ts65Dn mice in a learning and memory
test after an acute injection of the uncompetitive NMDAR
antagonist memantine has also been recently recorded.22
Despite the great relevance of the above data, there is
currently no treatment that speciﬁcally aims to normalize
the gene expression levels of critical aneuploidy genes.
With the approach described in the current study, we
have deﬁned the association of the normalization of
Dyrk1A protein levels with the rescue of the motor pheno-
type. It should be noted that the effect was found to be
long-lasting, because it was still signiﬁcant eight months
after injection, thus suggesting that the phenotype amelio-
ration achieved could indeed be far longer lasting. In fact,
the improved performance in the activity test was more
signiﬁcant at 4 than at 2 months after treatment, suggest-
ing that prolonged Dyrk1A normalized expression facili-
tates the correction of striatal-dependent phenotypes.
Importantly, the AAVshDyrk1A therapy administered was
well tolerated as evidenced by the lack of neurotoxicity
to the tested shRNA sequences targeting Dyrk1A and to
the absence of any deleterious effect due to the reduction
in Dyrk1A expression in TgDyrk1A mice striatum.
The above data offer further support to the notion that
Dyrk1A plays an important role in the control of motor
activity. The participation of Dyrk1A in motor physiology
ﬁrst came to light with the behavioral analysis of different
models of Dyrk1A-dosage imbalance. TgDyrk1A mice pres-
ent motor abnormalities in the areas of coordination and
motor learning, with the organization of motor behavior
being the area most severely affected.8,10 On the other
hand, the haploinsufﬁcient murine model Dyrk1Aþ/,
which presents reduced levels of Dyrk1A, has been shown
to present hypoactivity23,24 similar to that of the mutant
ﬂies of Dyrk1A orthologous gene Drosophila mnb.25 Re-
cently, the truncation of Dyrk1A in a patient has also
been associated to a delay in gross motor development.26
Although it is generally believed that these phenotypes
might derive from aberrant brain development, the motor
phenotype rescue in adult mice observed in our study
would suggest an active role for Dyrk1A in the neural pro-
cesses that take place in the mature brain. The current
study also highlights the contribution of the striatum to
the motor phenotype of TgDyrk1A mice. In this respect,
Dyrk1A has been shown to be highly expressed in the adult
mice striatum, indicating that the kinase may play an
important role in such structure.27 Moreover, recent obser-
vations have shown that the correct levels of Dyrk1A are
essential to the proper functioning of the nigrostriataldopaminergic neurons,28 which are thought to play a key
role in modulating excitatory neurotransmission in motor
circuitry.29
Therefore, the results obtained in the present study dem-
onstrate that the normalization of Dyrk1A gene expression
reverses the motor phenotypes of transgenic Dyrk1A mice.
This strategy provides a proof of concept on the Dyrk1A-
phenotype dependency. In principle, it could be specu-
lated that the spatial-learning phenotype also present in
thesemice could be rescued by applying a similar approach
with adequate AAV serotypes targeting the hippocampus.
On the other hand, it is clear that the real potential of
the present strategy is yet to be investigated in the trisomic
context in the existing partial trisomic mouse models. In
this case, if Dyrk1A is a major candidate gene in motor
and learning phenotypes, its normalization could also
have beneﬁcial effects. However we have to bear in mind
that in the trisomic context, many other genes are overex-
pressed that may inﬂuence on the normalization effects.
Moreover, the strategy developed in the current work can
be further applied to identify the role of additional genes
that might be considered therapeutic targets in Down
syndrome.
Supplemental Data
Supplemental Data include one ﬁgure and can be found with this
article online at http://www.ajhg.org/.
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